A	C177536	GDC Property Terminology	C102704	Reason Treatment Not Administered	The reason the treatment was not administered.	reason_treatment_not_given	reason treatment not given
A	C177536	GDC Property Terminology	C187352	Myasthenia Gravis Foundation of America Class	A finding associated with a patient with myasthenia gravis that is based on the classification system developed by the Myasthenia Gravis Foundation of America (MGFA) for grading myasthenia gravis that divides the disease into 5 main classes and several subclasses.	myasthenia_gravis_classification	myasthenia gravis classification
A	C177536	GDC Property Terminology	C202134	Number of Days Between Index Date and Pathology Review	The number of days between the index date and the date a sample was subjected to pathologic review.	days_to_pathology_detail	days to pathology detail
A	C177536	GDC Property Terminology	C202136	Average Number of Exercise Days per Week	A question regarding the average number of days per week a subject exercises.	exercise_frequency_weekly	exercise frequency weekly
A	C177536	GDC Property Terminology	C202137	Extracapsular Extension Present Indicator	An indication of whether extracapsular extension is present in a sample.	extracapsular_extension_present	extracapsular extension present
A	C177536	GDC Property Terminology	C202138	Extrathyroid Extent Indicator	An indication of the TNM finding that describes the degree of invasion of adjacent tissues for a primary tumor in the thyroid.	extrathyroid_extension	extrathyroid extension
A	C177536	GDC Property Terminology	C202139	Histological Progression Type	The type of disease progression identified during histologic image analysis.	histologic_progression_type	histologic progression type
A	C177536	GDC Property Terminology	C202140	Micrometastasis Present Indicator	An indication of whether micrometastases were present in a sample.	micrometastasis_present	micrometastasis present
A	C177536	GDC Property Terminology	C202155	Non-Oncologic Therapeutic Agent	A therapeutic agent given to a subject to treat non-oncologic conditions.	nononcologic_therapeutic_agents	nononcologic therapeutic agents
A	C177536	GDC Property Terminology	C202157	Therapeutic Oxygen Use Indicator	An indication as to whether supplemental oxygen was administered to the subject.	oxygen_use_indicator	oxygen use indicator
A	C177536	GDC Property Terminology	C202158	Home Oxygen Therapy Use Duration Indicator	An indication as to whether a subject used supplemental oxygen in the home continuously or intermittently.	oxygen_use_type	oxygen use type
A	C177536	GDC Property Terminology	C202159	Radiosensitizing Agent Used Indicator	An indication as to whether a radiosensitizing agent was administered.	radiosensitizing_agent	radiosensitizing agent
A	C177536	GDC Property Terminology	C202160	Number of Values in Staining Intensity Scale	The number of values in the qualitative scale used to score staining intensity findings.	staining_intensity_scale	staining intensity scale
C	C177536	GDC Property Terminology	C127762	Staining Intensity	The degree or magnitude of staining by a dye or reagent within a microscopic specimen.	staining_intensity_value	staining intensity value
C	C177536	GDC Property Terminology	C159315	FEV1% REF Pre-Bronchodilator	The test for pre-bronchodilator lung forced expiratory volume 1 test lab percentage value.	fev1_ref_pre_bronch_percent	fev1 ref pre bronch percent
C	C177536	GDC Property Terminology	C159316	FEV1% REF Post-Bronchodilator	The test for post-bronchodilator lung forced expiratory volume 1 test lab percentage value.	fev1_ref_post_bronch_percent	fev1 ref post bronch percent
C	C177536	GDC Property Terminology	C198198	Therapeutic Agent Level Achieved Indicator	An indication that the intended level of therapeutic agent was achieved in an individual.	therapeutic_levels_achieved	therapeutic levels achieved
C	C177536	GDC Property Terminology	C200444	Tumor Measurement Method	The methodology used to measure the size of a tumor.	measurement_type	measurement type
D	C177537	GDC Value Terminology	C1377	Hematoporphyrin Derivative	A complex mixture of monomeric and aggregated porphyrins with photosensitizing activity. Upon systemic administration, hematoporphyrin derivatives accumulate in tumor cells and, once activated by red laser light (630 nm), in the presence of oxygen, produce singlet oxygen and other reactive oxygen radicals, resulting in local radical-mediated tumor cell death.	Hematoporphyrin Derivative | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C167120	Recombinant Erwinia asparaginase JZP-458	A recombinant form of asparaginase (Erwinia asparaginase; crisantaspase) derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration of recombinant Erwinia asparaginase JZP-458, the recombinant asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. JZP-458 can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.	Recombinant Erwinia asparaginase JZP-458 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C170909	Anti-PD-1/VEGF Bispecific Antibody AK112	A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration of anti-PD-1/VEGF bispecific antibody AK112, this agent simultaneously targets and binds to both PD-1 expressed on certain T-cells and VEGF. The binding of AK112 to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) and/or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of AK112 to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands PD-L1/ or PD-L2; it plays an important role in tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.	Anti-PD-1/VEGF Bispecific Antibody AK112 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C45512	Lung Colloid Adenocarcinoma	A morphologic variant of lung adenocarcinoma characterized by the presence of mucin pools containing islands of well differentiated adenocarcinoma cells.	8472/1 | morphology || Mucinous cystic tumor of borderline malignancy | primary_diagnosis || Mucinous cystic tumor of borderline malignancy | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C8381	Florid Cemento-Osseous Dysplasia	Cemento-osseous dysplasia with multifocal (multiquadrant) involvement. (WHO 2017)	9275/0 | morphology || Florid osseous dysplasia | primary_diagnosis || Gigantiform cementoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C101153	Leukosialin	Leukosialin (400 aa, ~40 kDa) is encoded by the human SPN gene. This protein is involved in immune cell function.	CD43 | antigen	C268	antigen
A	C177537	GDC Value Terminology	C102532	Lymphoid Hyperplasia	A benign or malignant, diffuse and/or follicular lymphocytic proliferation.	Lymphoid Hyperplasia | comorbidities || Lymphoid Hyperplasia | risk_factors	C16457 || C17103	comorbidities || risk_factors
A	C177537	GDC Value Terminology	C112014	Myasthenia Gravis Foundation of America Class I	Myasthenia gravis presenting with any ocular weakness; may have weakness of eye closure. All other muscles strength is normal.	Class I | myasthenia_gravis_classification	C187352	myasthenia_gravis_classification
A	C177537	GDC Value Terminology	C112015	Myasthenia Gravis Foundation of America Class II	Myasthenia gravis presenting with mild weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.	Class II | myasthenia_gravis_classification	C187352	myasthenia_gravis_classification
A	C177537	GDC Value Terminology	C112016	Myasthenia Gravis Foundation of America Class III	Myasthenia gravis presenting with moderate weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.	Class III | myasthenia_gravis_classification	C187352	myasthenia_gravis_classification
A	C177537	GDC Value Terminology	C112017	Myasthenia Gravis Foundation of America Class IV	Myasthenia gravis presenting with severe weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.	Class IV | myasthenia_gravis_classification	C187352	myasthenia_gravis_classification
A	C177537	GDC Value Terminology	C112018	Myasthenia Gravis Foundation of America Class V	Myasthenia gravis presenting with severe muscle weakness that requires intubation, with or without mechanical ventilation, except when employed during routine postoperative management.	Class V | myasthenia_gravis_classification	C187352	myasthenia_gravis_classification
A	C177537	GDC Value Terminology	C151974	Occasionally	Not frequently or regularly.	Occasionally | treatment_frequency	C89081	treatment_frequency
A	C177537	GDC Value Terminology	C1655	HMG-CoA Reductase Inhibitor	Any substance that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Inhibition of HMG-CoA reductase acts to lower plasma cholesterol and lipoprotein levels.	Statin, NOS | nononcologic_therapeutic_agents	C202155	nononcologic_therapeutic_agents
A	C177537	GDC Value Terminology	C16853	Microscopy	The use of various technologies to resolve the structure or features of objects too small or fine to naturally be seen by eye.	Microscopy, NOS | molecular_analysis_method	C19770	molecular_analysis_method
A	C177537	GDC Value Terminology	C17230	Ultrasound Imaging	The use of high-frequency sound waves to generate images of the body.	Ultrasound | imaging_type	C17369	imaging_type
A	C177537	GDC Value Terminology	C184865	Ivonescimab	A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, ivonescimab simultaneously targets and binds to both PD-1 expressed on certain T-cells and VEGF expressed on tumor cells. The binding of ivonescimab to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of ivonescimab to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands PD-L1 and/or PD-L2; it plays an important role in tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.	Anti-PD-1/VEGF Bispecific Antibody AK112 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C185467	Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype	An aggressive, WHO grade 4 diffuse brain glioma usually affecting children, adolescents, or young adults. It is characterized by the absence of histone H3, IDH1, and IDH2 mutations. It includes the following subtypes, based on DNA methylation profiles: diffuse pediatric-type high grade glioma RTK1, diffuse pediatric-type high grade glioma RTK2, and diffuse pediatric-type high grade glioma MYCN.	Diffuse Pediatric-type High Grade Glioma | primary_diagnosis	C177621	primary_diagnosis
A	C177537	GDC Value Terminology	C185642	Scheduling Issue	A problem scheduling an event.	Scheduling Problems | reason_treatment_not_given	C102704	reason_treatment_not_given
A	C177537	GDC Value Terminology	C186199	Staining Intensity 0	A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.	0 | staining_intensity_value	C127762	staining_intensity_value
A	C177537	GDC Value Terminology	C186200	Staining Intensity 1+	A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.	1+ | staining_intensity_value	C127762	staining_intensity_value
A	C177537	GDC Value Terminology	C186201	Staining Intensity 2+	A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.	2+ | staining_intensity_value	C127762	staining_intensity_value
A	C177537	GDC Value Terminology	C186202	Staining Intensity 3+	A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.	3+ | staining_intensity_value	C127762	staining_intensity_value
A	C177537	GDC Value Terminology	C192979	Refusal of Treatment by Patient	An indication that the patient has refused treatment.	Participant Refusal | reason_treatment_not_given	C102704	reason_treatment_not_given
A	C177537	GDC Value Terminology	C198	Acetaminophen	A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.	Acetaminophen | nononcologic_therapeutic_agents	C202155	nononcologic_therapeutic_agents
A	C177537	GDC Value Terminology	C201135	Goblet Cell Adenocarcinoma	A rare adenocarcinoma that exhibits neuroendocrine differentiation and is associated with the presence of neoplastic signet-ring cells resembling goblet cells of the intestine.	8243/3 | morphology || 8245/3 | morphology || Adenocarcinoid tumor | primary_diagnosis || Composite carcinoid | primary_diagnosis || Goblet Cell Carcinoid | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C201136	Solid Pseudopapillary Neoplasm	A low-grade malignant neoplasm that arises from the exocrine pancreas. Rare cases arising from ectopic pancreatic tissue in the ovary have also been described. It is characterized by the presence of uniform cells that form solid and pseudopapillary patterns, cystic changes, and hemorrhage. It usually presents as an encapsulated, solitary, and lobulated mass. It occurs predominantly in young women. Complete removal of the tumor is curative in the majority of cases.	8452/1 | morphology || Solid pseudopapillary tumor | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C201978	Pulmonary Mucinous Cystic Tumor of Borderline Malignancy	A very rare, non-invasive epithelial neoplasm that arises from the lung. It is composed of multilocular cysts filled with mucus. The cysts are lined with columnar mucinous epithelium. Focal cellular atypia is present.	8472/1 | morphology || Mucinous cystic tumor of borderline malignancy | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C202077	Central Odontogenic Fibroma	An odontogenic fibroma that arises from tooth-forming tissues in the mandible and maxilla.	9321/0 | morphology || Central odontogenic fibroma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C202212	Exercised Five or More Days per Week	A response indicating that a subject exercised 5 or more days per week.	5 or More Days | exercise_frequency_weekly	C202136	exercise_frequency_weekly
A	C177537	GDC Value Terminology	C202213	Exercised Three to Four Days per Week	A response indicating that a subject exercised 3 to 4 days per week.	3 to 4 Days | exercise_frequency_weekly	C202136	exercise_frequency_weekly
A	C177537	GDC Value Terminology	C202214	Exercised One to Two Days per Week	A response indicating that a subject exercised 1 to 2 days per week.	1 to 2 Days | exercise_frequency_weekly	C202136	exercise_frequency_weekly
A	C177537	GDC Value Terminology	C202215	0-30 Days	A time period between 0 and 30 days.	0-30 Days | first_symptom_longest_duration	C200443	first_symptom_longest_duration
A	C177537	GDC Value Terminology	C202216	31-90 Days	A time period between 31 and 90 days.	31-90 Days | first_symptom_longest_duration	C200443	first_symptom_longest_duration
A	C177537	GDC Value Terminology	C202217	91-180 Days	A time period between 91 and 180 days.	91-180 Days | first_symptom_longest_duration	C200443	first_symptom_longest_duration
A	C177537	GDC Value Terminology	C202218	Greater than or Equal to 181 Days	A time period of at least 181 days.	>=181 Days | first_symptom_longest_duration	C200443	first_symptom_longest_duration
A	C177537	GDC Value Terminology	C202219	Gigantiform Cementoma	An extremely rare, benign, rapidly progressing fibro-osseous lesion that arises from the jaws as a multifocal expansile growth in children or adolescents. It results in significant deformity, orbital distortion, and possible airway involvement. An autosomal dominant inheritance has been proposed. Histologically, it is characterized by the presence of immature bony trabeculae and cementum-like calcifications within a hypercellular fibroblastic stroma. It shares morphological features with florid cemento-osseous dysplasia, but in florid cemento-osseous dysplasia the degree of expansion is less prominent and patients are usually older.	9275/0 | morphology || Florid osseous dysplasia | primary_diagnosis || Gigantiform cementoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C202251	CT2584 Mesylate	The mesylate form of CT-2584, a lipid metabolism and phosphatidic acid modulator, with potential antineoplastic activity. Upon administration, CT-2584 inhibits phospholipid signaling which may inhibit tumor cell proliferation.	CT2584 HMS | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C202267	Treatment not Administered per the Discretion of the Health Care Provider	The treatment was not administered per the discretion of the health care provider.	Not Done per Treating Physician's Discretion | reason_treatment_not_given	C102704	reason_treatment_not_given
A	C177537	GDC Value Terminology	C202268	Three Point Scale for Staining Intensity	A scale for staining intensity with three values.	3 Point Scale | staining_intensity_scale	C202160	staining_intensity_scale
A	C177537	GDC Value Terminology	C202269	Four Point Scale for Staining Intensity	A scale for staining intensity with four values.	4 Point Scale | staining_intensity_scale	C202160	staining_intensity_scale
A	C177537	GDC Value Terminology	C202273	Staining Intensity 4+	A measurement of the amount or proportion of tissue or cells that have a staining intensity of 4+.	4+ | staining_intensity_value	C127762	staining_intensity_value
A	C177537	GDC Value Terminology	C202274	Mitotic Count Reported Indicator	An indication that a mitotic count was reported for a sample.	Mitotic Count Reported | test_result	C36292	test_result
A	C177537	GDC Value Terminology	C202275	Staining Intensity Value Reported Indicator	An indication that a staining intensity value was reported for a sample.	Staining Intensity Value Reported | test_result	C36292	test_result
A	C177537	GDC Value Terminology	C202276	Once a Week for at Least a Year	An indication that something was scheduled, or occurred, once a week for at least a year.	Once a Week for at Least a Year | treatment_frequency	C89081	treatment_frequency
A	C177537	GDC Value Terminology	C202277	Affymetrix Genome-Wide Human SNP Array 6.0	A proprietary system comprised of a single microarray with over 900,000 single nucleotide polymorphisms (SNPs) for genome-wide profiling and approximately 945,000 non-polymorphic probes for detection of copy number variation across a genomic sample.	Affymetrix SNP 6.0 | platform	C45378	platform
A	C177537	GDC Value Terminology	C202294	Home-related Exposure	Exposure to potentially harmful chemical, physical, or biological agents in the home.	Home | exposure_source	C188372	exposure_source
A	C177537	GDC Value Terminology	C202295	Social Setting-related Exposure	Exposure to potentially harmful chemical, physical, or biological agents when interacting with other individuals.	Social | exposure_source	C188372	exposure_source
A	C177537	GDC Value Terminology	C202296	Continuous Oxygen Administration	Long-term administration of supplementary oxygen at a constant rate using a continuous flow device.	Continuous | oxygen_use_type	C202158	oxygen_use_type
A	C177537	GDC Value Terminology	C202297	Intermittent Oxygen Administration	Administration of supplementary oxygen over a short period of time using a non-continuous flow device.	Intermittent | oxygen_use_type	C202158	oxygen_use_type
A	C177537	GDC Value Terminology	C26785	Goiter	Enlargement of the thyroid gland usually caused by lack of iodine in the diet, hyperthyroidism, or thyroid nodules. Symptoms include difficulty in breathing and swallowing.	Goiter | comorbidities || Goiter | risk_factors	C16457 || C17103	comorbidities || risk_factors
A	C177537	GDC Value Terminology	C287	Aspirin	An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.	Aspirin | nononcologic_therapeutic_agents	C202155	nononcologic_therapeutic_agents
A	C177537	GDC Value Terminology	C2959	Complication	Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure.	Adverse Event/Complications | reason_treatment_not_given	C102704	reason_treatment_not_given
A	C177537	GDC Value Terminology	C3071	Graves Disease	Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.	Graves' Disease | comorbidities || Graves' Disease | risk_factors	C16457 || C17103	comorbidities || risk_factors
A	C177537	GDC Value Terminology	C3123	Hyperthyroidism	Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor.	Hyperthyroidism | comorbidities || Hyperthyroidism | risk_factors	C16457 || C17103	comorbidities || risk_factors
A	C177537	GDC Value Terminology	C32887	Thyroid Gland Isthmus	The narrow, central portion of the thyroid gland that crosses the trachea anteriorly and connects the lateral lobes of the gland. When present, the normal variant pyramidal lobe may extend from the isthmus.	Thyroid Gland Isthmus | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C3415	Thyroid Gland Nodule	A nodular lesion that develops in the thyroid gland.  Causes include adenoma, thyroiditis, fluid-filled cyst, multinodular goiter, and carcinoma.	Benign Thyroid Nodule | comorbidities || Benign Thyroid Nodule | risk_factors	C16457 || C17103	comorbidities || risk_factors
A	C177537	GDC Value Terminology	C36132	Poorly Differentiated Lesion	A lesion comprised of neoplastic cells that generally have lost most of the morphological features that are indicative of normal cells.	Poorly differentiated | histologic_progression_type	C202139	histologic_progression_type
A	C177537	GDC Value Terminology	C48259	Hyperparathyroidism	Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.	Hyperparathyroidism | comorbidities || Hyperparathyroidism | risk_factors	C16457 || C17103	comorbidities || risk_factors
A	C177537	GDC Value Terminology	C70543	Never	Not ever; at no time in the past (or future).	Never | treatment_frequency	C89081	treatment_frequency
C	C177537	GDC Value Terminology	C121849	Ezobresib	An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, ezobresib binds to the acetyl-lysine binding site in the BRD of BET proteins, thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes, resulting in an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.	BET Inhibitor BMS-986158 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C161016	Non-Keratinizing Dysplasia	Intraepithelial proliferation of dysplastic epithelial cells not associated with keratin formation.	Nonkeratinizing | dysplasia_type	C4086	dysplasia_type
C	C177537	GDC Value Terminology	C161017	Keratinizing Dysplasia	Epithelial dysplasia in which the dysplastic changes, although limited to the lower basal zone, are so severe, that there is a high probability of progression to invasive carcinoma.	Keratinizing | dysplasia_type	C4086	dysplasia_type
C	C177537	GDC Value Terminology	C1729	CT2584	A lipid metabolism and phosphatidic acid modulator, with potential antineoplastic activity. Upon administration, CT-2584 inhibits phospholipid signaling which may inhibit tumor cell proliferation.	CT2584 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C100089	Interferon Gamma-1b	A recombinant form of the endogenous cytokine human interferon (IFN) gamma-1b, with immunomodulating activity. Upon administration, IFN gamma-1b targets, binds to, and activates the cell-surface IFN-gamma receptor, stimulating antibody dependent cellular cytotoxicity (ADCC), activating natural killer (NK) cells, and enhancing the oxidative metabolism of macrophages. IFN-gamma plays important roles in the innate and adaptive immune responses.	Interferon Gamma-1b | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C1071	Porfimer Sodium	The sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm wavelength laser light, resulting in tumor cell cytotoxicity. In addition, tumor cell death may occur due to ischemic necrosis secondary to vascular occlusion that appears to be partly mediated by the release of thromboxane A2.	Hematoporphyrin Derivative | therapeutic_agents || Porfimer Sodium | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C113439	PSMA-targeting Fluorescent Imaging Agent MDX1201-A488	A recombinant, human monoclonal antibody targeting an extracellular epitope of human prostate specific membrane antigen (PSMA) that is conjugated with A488, a photostable fluorescent dye with a high quantum yield, with potential imaging activity. Upon intravenous administration of PSMA-targeting fluorescent imaging agent MDX1201-A488, the MDX1201 moiety targets PSMA expressed on cancer cells. Subsequently, the A488 moiety can then be visualized by fluorescence-based imaging and the amount of PSMA-expressing tumor cells can be assessed. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.	Anti-PSMA Monoclonal Antibody MDX1201-A488 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C116750	Dilpacimab	A bispecific, tetravalent immunoglobulin (Ig) G-like molecule containing the target-binding variable domains of two monoclonal antibodies, one targeting the Notch ligand delta-like 4 (DLL4) and the other one targeting the human tyrosine kinase vascular endothelial growth factor (VEGF), combined via linkers, with potential anti-angiogenic and antineoplastic activities. Upon administration, dilpacimab targets and binds to both DLL4 and VEGF. This prevents the activation of DLL-4/Notch- and VEGF/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt tumor cell proliferation. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.	Dilpacimab | therapeutic_agents || Dual Variable Domain Immunoglobulin ABT-165 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C118669	Sulanemadlin	An orally available peptide inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, sulanemadlin binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells.	MDM2/MDMX Inhibitor ALRN-6924 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C118671	Abivertinib Maleate Anhydrous	The maleate salt form of abivertinib, an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.	Avitinib Maleate | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12228	Base of Tongue	The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oro-pharynx responsible for swallowing and modification of the voice in speech.	Base of tongue | primary_site || Base of tongue, NOS | progression_or_recurrence_anatomic_site || Base of tongue, NOS | site_of_resection_or_biopsy || Base of tongue, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C124227	Adakitug	A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, adakitug directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, BMS-986253 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.	Anti-IL-8 Monoclonal Antibody BMS-986253 | therapeutic_agents || Anti-IL-8 Monoclonal Antibody HuMax-IL8 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C125006	Pathologic Examination	An assessment of disease process to include cause, development, and/or structural and functional changes associated with the disease.	Pathologic | measurement_type || Pathologic | tumor_measurement_method || Pathologic Review | method_of_diagnosis	C177576 || C200444	method_of_diagnosis || measurement_type
C	C177537	GDC Value Terminology	C12745	Lymph Node	A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.	Lymph Noce | imaging_anatomic_site || Lymph Node | biospecimen_anatomic_site || Lymph Node | treatment_anatomic_sites || Lymph node, NOS | progression_or_recurrence_anatomic_site || Lymph node, NOS | site_of_resection_or_biopsy || Lymph node, NOS | sites_of_involvement || Lymph node, NOS | tissue_or_organ_of_origin || Lymph nodes | primary_site	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C182312 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || imaging_anatomic_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C132681	Anti-CD40/Anti-mesothelin Bispecific Antibody ABBV-428	A bispecific antibody directed against both the cell-surface receptor CD40 and the tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunostimulatory and antineoplastic activities. Upon administration of anti-CD40/anti-MSLN bispecific antibody ABBV-428, the anti-MSLN moiety targets and binds to MSLN expressed on tumor cells. The agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells in the tumor microenvironment (TME) and induces CD40-dependent signaling pathways, which triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B-lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.	Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C148145	Lutetium Lu 177 Vipivotide Tetraxetan	A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.	Lutetium Lu 177-PSMA-617 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C148513	ALK/c-Met Inhibitor TQ-B3139	An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.	ALK/c-Met Inhibitor TQ-B3139 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C153372	Lixumistat Acetate	The acetate salt form of lixumistat, an orally bioavailable biguanide compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration, lixumistat inhibits oxidative phosphorylation, decreases mitochondrial function, prevents tumor cell metabolism and deprives tumor cells of energy, thereby preventing tumor cell proliferation. Mitochondrial OxPhos is overactivated in cancer cells and plays a key role in tumor cell proliferation. Drug resistant tumor cells are very susceptible to decreased mitochondrial OxPhos as they cannot easily compensate for the decrease in mitochondrial function by increasing glycolysis.	Oxidative Phosphorylation Inhibitor IM156 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C155738	Histone H3.Y	Histone H3.Y (136 aa, ~15 kDa) is encoded by the human H3Y1 gene. This protein may be involved in both the positive regulation of transcription and the formation of higher order chromatin structures.	H3.Y | histone_variant	C177620	histone_variant
C	C177537	GDC Value Terminology	C162535	Dasminapant	A small molecule, second mitochondria-derived activator of caspases (SMAC)-mimetic targeting inhibitor of apoptosis proteins (IAPs) with potential apoptosis-inducing and antineoplastic activities. Upon administration, dasminapant selectively binds to and inhibits the activity of IAPs including X chromosome-linked IAP (XIAP) and cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This may restore and promote the induction of apoptosis through apoptotic signaling pathways and enhance proteasomal degradation of IAPs. Additionally, dasminapant may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.	IAP Inhibitor APG-1387 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C162623	Normal Tissue Sample	Tissue sample with cellular composition and architectural patterns expected for the particular anatomic site in which it belongs. There is no evidence of abnormal cellular infiltrates or tumor mass formation.	Uninvolved Tissue, NOS | biospecimen_type	C83315	biospecimen_type
C	C177537	GDC Value Terminology	C164022	First Treatment Date	The date for the initiation of a patient treatment plan.	First Treatment | index_date || First Treatment | timepoint_category	C146721 || C198201	index_date || timepoint_category
C	C177537	GDC Value Terminology	C164218	SHP2 Inhibitor JAB-3312	An orally bioavailable allosteric inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3312 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements, which are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.	KRAS-MAPK Signaling Pathway Inhibitor JAB-3312 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C164250	Human Papillomavirus-Independent Squamous Cell Carcinoma	A squamous cell carcinoma not associated with human papilloma virus infection.	8086/3 | morphology || Squamous cell carcinoma, HPV-negative | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C166409	Anti-TROP2 Antibody-drug Conjugate MK-2870	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration of the anti-TROP2 ADC SKB264, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.	Anti-TROP2 Antibody-drug Conjugate SKB264 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C16929	Occupational Exposure	The exposure to potentially harmful agents that occurs as a result of one's occupation.	Occupational | exposure_source || Work | exposure_source	C188372	exposure_source
C	C177537	GDC Value Terminology	C171150	Tumor-Associated Lymphocytosis	Non-neoplastic lymphocytosis associated with the presence of a tumor.	Tumor-associated Lymphoid Proliferation | risk_factors || Tumor-associated lymphoid proliferation | additional_pathology_findings	C158809 || C17103	additional_pathology_findings || risk_factors
C	C177537	GDC Value Terminology	C171370	Copper Cu 67 Ucasareotide Dasaroxetan	A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional chelator 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar) and radiolabeled with the beta-emitting radioisotope copper Cu 67, with potential antineoplastic activity. Upon administration, copper Cu 67 ucasareotide dasaroxetan binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. TATE is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.	Copper Cu 67 Tyr3-octreotate | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172821	Trastuzumab/MMAF Antibody-drug Conjugate IKS014	An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting the tumor-associated antigen (TAA) epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), site-specifically conjugated, via a tumor-selective beta-glucuronide linker, to the auristatin analog and potent microtubule inhibitor monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of trastuzumab/MMAF ADC IKS014, the trastuzumab moiety targets and binds to HER2 expressed on tumor cells. Upon binding, internalization and linker cleavage, MMAF is released. MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Trastuzumab Monomethyl Auristatin F | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173165	Ficerafusp Alfa	A bifunctional monoclonal antibody targeting both the receptor tyrosine kinase epidermal growth factor receptor (EGFR) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration of ficerafusp alfa, the anti-EGFR moiety targets, binds to and prevents activation of EGFR-mediated signaling. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. The anti-TGFb moiety targets and binds to TGFb, thereby preventing the activation of TGFb-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGFb is overactivated. EGFR and TGFb, mutated and/or overexpressed on the surfaces of various tumor cell types, play key roles in tumor cell proliferation and progression.	EGFR/TGFb Fusion Monoclonal Antibody BCA101 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173547	Gotistobart	A humanized, pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, gotistobart targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. As gotistobart is dissociated from CTLA-4 under low pH, it does not cause lysosomal degradation of CTLA-4, preserving CTLA-4 and allowing the recycling of CTLA-4. This may result in more efficient and selective CTLA-4-targeted regulatory T-cell (Treg) depletion within the tumor microenvironment (TME) while preserving CTLA-4 functions outside the TME, thereby reducing toxicities. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Anti-CTLA-4 Monoclonal Antibody ONC-392 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173701	Ginisortamab	A monoclonal antibody directed against gremlin-1 (GREM1; Drm), with potential antineoplastic activity. Upon administration, ginisortamab specifically targets and binds to gremlin-1, thereby neutralizing Gremlin-1. This may block the gremlin-1-mediated inhibition of bone morphogenetic protein (BMP) signaling pathways, and may lead to the inhibition of tumor cell growth and proliferation. Gremlin-1, a BMP antagonist that is overexpressed in a variety of cancer cell types, is involved in cancer cell growth and proliferation as well as tissue fibrosis.	Anti-gremlin-1 Monoclonal Antibody UCB6114 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173740	Ameloblastic Fibro-Odontosarcoma	An odontogenic sarcoma producing enamel/enameloid and dentin.	9290/3 | morphology || Ameloblastic fibro-odontosarcoma | primary_diagnosis || Ameloblastic odontosarcoma | primary_diagnosis || Odontogenic fibrosarcoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C17998	Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	Unknown | adapter_content || Unknown | ajcc_clinical_m || Unknown | ajcc_clinical_n || Unknown | ajcc_clinical_stage || Unknown | ajcc_clinical_t || Unknown | ajcc_pathologic_m || Unknown | ajcc_pathologic_n || Unknown | ajcc_pathologic_stage || Unknown | ajcc_pathologic_t || Unknown | ajcc_staging_system_edition || Unknown | alcohol_history || Unknown | alcohol_intensity || Unknown | alcohol_type || Unknown | anaplasia_present || Unknown | anaplasia_present_type || Unknown | ann_arbor_b_symptoms || Unknown | ann_arbor_clinical_stage || Unknown | ann_arbor_extranodal_involvement || Unknown | ann_arbor_pathologic_stage || Unknown | antigen || Unknown | barretts_esophagus_goblet_cells_present || Unknown | basic_statistics || Unknown | biospecimen_anatomic_site || Unknown | biospecimen_laterality || Unknown | biospecimen_type || Unknown | bone_marrow_malignant_cells || Unknown | burkitt_lymphoma_clinical_variant || Unknown | cause_of_death || Unknown | cause_of_death_source || Unknown | cdc_hiv_risk_factors || Unknown | chemo_concurrent_to_radiation || Unknown | child_pugh_classification || Unknown | chipseq_antibody || Unknown | chipseq_target || Unknown | chromosomal_translocation || Unknown | chromosome || Unknown | classification_of_tumor || Unknown | cog_liver_stage || Unknown | cog_neuroblastoma_risk_group || Unknown | cog_renal_stage || Unknown | cog_rhabdomyosarcoma_risk_group || Unknown | columnar_mucosa_present || Unknown | comorbidities || Unknown | comorbidity_method_of_diagnosis || Unknown | diabetes_treatment_type || Unknown | diagnosis_pathologically_confirmed || Unknown | disease_response || Unknown | disease_type || Unknown | distance_normal_to_tumor || Unknown | dysplasia_degree || Unknown | dysplasia_type || Unknown | ecog_performance_status || Unknown | eln_risk_classification || Unknown | enneking_msts_grade || Unknown | enneking_msts_metastasis || Unknown | enneking_msts_stage || Unknown | enneking_msts_tumor_site || Unknown | environmental_tobacco_smoke_exposure || Unknown | esophageal_columnar_dysplasia_degree || Unknown | esophageal_columnar_metaplasia_present || Unknown | ethnicity || Unknown | exposure_duration || Unknown | exposure_source || Unknown | extracapsular_extension_present || Unknown | extrathyroid_extension || Unknown | figo_stage || Unknown | first_symptom_prior_to_diagnosis || Unknown | fragmentation_enzyme || Unknown | gastric_esophageal_junction_involvement || Unknown | gene_symbol || Unknown | goblet_cells_columnar_mucosa_present || Unknown | haart_treatment_indicator || Unknown | hepatitis_sustained_virological_response || Unknown | histologic_progression_type || Unknown | histone_family || Unknown | histone_variant || Unknown | hormonal_contraceptive_type || Unknown | hormonal_contraceptive_use || Unknown | hormone_replacement_therapy_type || Unknown | hysterectomy_margins_involved || Unknown | hysterectomy_type || Unknown | igcccg_stage || Unknown | imaging_result || Unknown | immunosuppressive_treatment_type || Unknown | initial_disease_status || Unknown | inpc_grade || Unknown | inpc_histologic_group || Unknown | inrg_stage || Unknown | inss_stage || Unknown | instrument_model || Unknown | irs_group || Unknown | irs_stage || Unknown | ishak_fibrosis_score || Unknown | iss_stage || Unknown | karnofsky_performance_status || Unknown | kmer_content || Unknown | laboratory_test || Unknown | largest_extrapelvic_peritoneal_focus || Unknown | laterality || Unknown | lost_to_followup || Unknown | lymph_node_involved_site || Unknown | lymph_node_involvement || Unknown | lymphatic_invasion_present || Unknown | margin_status || Unknown | medulloblastoma_molecular_classification || Unknown | menopause_status || Unknown | metaplasia_present || Unknown | metastasis_at_diagnosis || Unknown | method_of_diagnosis || Unknown | method_of_sample_procurement || Unknown | micrometastasis_present || Unknown | micropapillary_features || Unknown | mismatch_repair_mutation || Unknown | mitosis_karyorrhexis_index || Unknown | molecular_analysis_method || Unknown | morphology || Unknown | non_nodal_regional_disease || Unknown | non_nodal_tumor_deposits || Unknown | normal_tumor_genotype_snp_match || Unknown | ovarian_specimen_status || Unknown | ovarian_surface_involvement || Unknown | overrepresented_sequences || Unknown | oxygen_use_indicator || Unknown | per_base_n_content || Unknown | per_base_sequence_content || Unknown | per_base_sequence_quality || Unknown | per_sequence_gc_content || Unknown | per_sequence_quality_score || Unknown | per_tile_sequence_quality || Unknown | perineural_invasion_present || Unknown | peripancreatic_lymph_nodes_positive || Unknown | peritoneal_fluid_cytological_status || Unknown | ploidy || Unknown | pregnancy_outcome || Unknown | pregnant_at_diagnosis || Unknown | premature_at_birth || Unknown | preservation_method || Unknown | primary_diagnosis || Unknown | primary_site || Unknown | prior_treatment || Unknown | procedures_performed || Unknown | progression_or_recurrence || Unknown | progression_or_recurrence_anatomic_site || Unknown | progression_or_recurrence_type || Unknown | race || Unknown | radiosensitizing_agent || Unknown | reason_treatment_not_given || Unknown | reflux_treatment_type || Unknown | relationship_primary_diagnosis || Unknown | relationship_type || Unknown | residual_disease || Unknown | risk_factor_treatment || Unknown | risk_factors || Unknown | satellite_nodule_present || Unknown | second_gene_symbol || Unknown | secondhand_smoke_as_child || Unknown | sequence_duplication_levels || Unknown | sequence_length_distribution || Unknown | site_of_resection_or_biopsy || Unknown | sites_of_involvement || Unknown | smoking_frequency || Unknown | specimen_type || Unknown | supratentorial_localization || Unknown | synchronous_malignancy || Unknown | target_capture_kit || Unknown | test_analyte_type || Unknown | test_result || Unknown | test_units || Unknown | therapeutic_agents || Unknown | therapeutic_levels_achieved || Unknown | time_between_waking_and_first_smoke || Unknown | tissue_or_organ_of_origin || Unknown | tissue_type || Unknown | tobacco_smoking_status || Unknown | transglottic_extension || Unknown | treatment_anatomic_sites || Unknown | treatment_effect || Unknown | treatment_effect_indicator || Unknown | treatment_frequency || Unknown | treatment_intent_type || Unknown | treatment_outcome || Unknown | treatment_type || Unknown | tumor_confined_to_organ_of_origin || Unknown | tumor_descriptor || Unknown | tumor_focality || Unknown | tumor_grade || Unknown | tumor_regression_grade || Unknown | tumor_shape || Unknown | type_of_smoke_exposure || Unknown | uicc_clinical_m || Unknown | uicc_clinical_n || Unknown | uicc_clinical_stage || Unknown | uicc_clinical_t || Unknown | uicc_pathologic_m || Unknown | uicc_pathologic_n || Unknown | uicc_pathologic_stage || Unknown | uicc_pathologic_t || Unknown | uicc_staging_system_edition || Unknown | variant_origin || Unknown | variant_type || Unknown | vascular_invasion_present || Unknown | vascular_invasion_type || Unknown | viral_hepatitis_serologies || Unknown | vital_status || Unknown | who_cns_grade || Unknown | who_nte_grade || Unknown | wilms_tumor_histologic_subtype || Unknown | zygosity || unknown | gender || unknown | prior_malignancy || unknown | progression_or_recurrence || unknown | relationship_gender || unknown | relative_with_cancer_history || unknown | treatment_or_therapy || unknown | vital_status	C102562 || C102704 || C105721 || C106304 || C106317 || C106541 || C111073 || C112400 || C121007 || C123560 || C125738 || C126378 || C127768 || C127772 || C129439 || C13202 || C133427 || C133706 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C15256 || C15599 || C156421 || C156422 || C157233 || C157410 || C157425 || C158874 || C159824 || C160720 || C160827 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C16515 || C16564 || C166229 || C16687 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173263 || C173544 || C17357 || C173595 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177570 || C177571 || C177572 || C177576 || C177578 || C177583 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177597 || C177598 || C177599 || C177600 || C177601 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177613 || C177614 || C177616 || C177619 || C177620 || C177621 || C177622 || C177624 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188372 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C198198 || C198206 || C200474 || C202137 || C202138 || C202139 || C202140 || C202157 || C202159 || C25185 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C29878 || C2991 || C33027 || C3420 || C35529 || C36037 || C36292 || C38032 || C4086 || C45824 || C45902 || C4809 || C49236 || C50995 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C95149 || C99532	inpc_grade || reason_treatment_not_given || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || alcohol_intensity || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || mismatch_repair_mutation || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || hysterectomy_type || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || primary_site || lost_to_followup || lymphatic_invasion_present || satellite_nodule_present || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidities || fragmentation_enzyme || ethnicity || tumor_descriptor || histone_family || ploidy || race || risk_factors || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || dysplasia_degree || target_capture_kit || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serologies || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || chipseq_antibody || chipseq_target || initial_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || exposure_source || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || therapeutic_levels_achieved || uicc_staging_system_edition || tumor_shape || extracapsular_extension_present || extrathyroid_extension || histologic_progression_type || micrometastasis_present || oxygen_use_indicator || radiosensitizing_agent || laterality || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || relative_with_cancer_history || disease_type || lymph_node_involved_site || chromosomal_translocation || lymph_node_involvement || tumor_confined_to_organ_of_origin || test_result || treatment_effect || dysplasia_type || zygosity || alcohol_type || residual_disease || treatment_or_therapy || disease_response || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || specimen_type || treatment_anatomic_sites || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || ishak_fibrosis_score || diabetes_treatment_type
C	C177537	GDC Value Terminology	C18009	Tumor Tissue Sample	Tissue sample that contains an abnormal cellular infiltrate forming a solid mass. The abnormal cellular component can be benign or malignant. Tumor samples are obtained for microscopic examination and/or molecular analysis.	Involved Tissue, NOS | biospecimen_type || Tumor | tissue_type	C19697 || C83315	tissue_type || biospecimen_type
C	C177537	GDC Value Terminology	C200433	Sonographic Examination	A medical examination of the internal anatomy of a subject using high-frequency sound waves to generate images.	Echographic | measurement_type	C200444	measurement_type
C	C177537	GDC Value Terminology	C26800	Hypothyroidism	Abnormally low levels of thyroid hormone.	Hypothyroidism | comorbidities || Hypothyroidism | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C27084	Spindle Cell Squamous Carcinoma	A poorly differentiated squamous cell carcinoma characterized by the presence of malignant cells with spindle cell features.	8074/3 | morphology || Epidermoid carcinoma, spindle cell | primary_diagnosis || Squamous cell carcinoma, sarcomatoid | primary_diagnosis || Squamous cell carcinoma, spindle cell | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C2897	Benign Prostatic Hyperplasia	A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow.	Benign Prostatic Hyperplasia | risk_factors || Nodular Prostatic Hyperplasia | risk_factors	C17103	risk_factors
C	C177537	GDC Value Terminology	C32298	Cervical Lymph Node	Any of the lymph nodes located in the neck.	Cervical lymph nodes | max_tumor_bulk_site || Cervical, NOS | lymph_node_involved_site || Lymph Node(s) Cervical | biospecimen_anatomic_site || Lymph Node(s) Cervical | treatment_anatomic_sites	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C34594	Escherichia coli Infection	Infection with the organism Escherichia Coli.	Escherichia coli | comorbidities || Escherichia coli | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C3502	Thyroid Gland Follicular Adenoma	A benign, encapsulated neoplasm arising from the follicular cells of the thyroid gland. It may be associated with thyroid hormone secretion but it does not have malignant characteristics.	8330/0 | morphology || Follicular Adenoma | comorbidities || Follicular Adenoma | risk_factors || Follicular adenoma | primary_diagnosis	C16457 || C17103 || C176985 || C177621	comorbidities || risk_factors || morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C35837	Sialoblastoma	A rare, malignant primitive neoplasm that occurs in the salivary glands. Most tumors arise from the parotid gland, followed by the submandibular gland, and rarely the minor salivary glands. It is usually diagnosed during the neonatal period and presents with painless face swelling.	8974/1 | morphology || Sialoblastoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C36113	Anaplastic Lesion	A morphologic finding indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample.	Anaplastic | histologic_progression_type || Present | anaplasia_present_type	C178287 || C202139	anaplasia_present_type || histologic_progression_type
C	C177537	GDC Value Terminology	C37212	Solid Pseudopapillary Neoplasm of the Pancreas	A low-grade malignant neoplasm that arises from the exocrine pancreas. It is characterized by the presence of uniform cells that form solid and pseudopapillary patterns, cystic changes, and hemorrhage. Perineural invasion, vascular invasion, and invasion into surrounding tissues may be present. It usually presents as an encapsulated, solitary, and lobulated pancreatic mass. It is usually found incidentally during physical examination or it may present with abdominal discomfort and pain. It occurs predominantly in young women. Complete removal of the tumor is curative in the majority of cases.	8452/3 | morphology	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C38766	Lymphocytic Thyroiditis	An inflammatory disorder that affects the thyroid gland.  It is characterized by the infiltration of the thyroid parenchyma by lymphocytes.  It includes Hashimoto thyroiditis and subacute lymphocytic thyroiditis.	Lymphocytic Thyroiditis | comorbidities || Lymphocytic Thyroiditis | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C38897	CD3 Complex	A protein complex comprised of one T-cell surface glycoprotein CD3 delta chain (CD3D), one T-cell surface glycoprotein CD3 gamma chain (CD3G) and two T-cell surface glycoprotein CD3 epsilon chains (CD3E). CD3D, CD3G and CD3E are transmembrane proteins with one extracellular immunoglobulin domain and one intracellular ITAM domain. The CD3 complex is a T-cell co-receptor that noncovalently associates with either the disulfide bound heterodimeric alpha/beta T-cell receptor (TCR) or gamma/delta TCR and two copies of the accessory protein, T-cell surface glycoprotein CD3 zeta chain (CD247), which is a transmembrane protein with three ITAM domains. The TCR moiety of the TCR-CD3 complex binds to MHC and processed antigens on antigen presenting cells, which triggers phosphorylation of and cellular propagation of the signal by CD247 and the CD3 complex.	CD3 | antigen	C268	antigen
C	C177537	GDC Value Terminology	C41132	None	No person or thing, nobody, not any.	No Treatment | reflux_treatment_type || None | exercise_frequency_weekly || None | extrathyroid_extension || None | first_event || None | immunosuppressive_treatment_type || None | lymph_node_involved_site || None | risk_factors	C17103 || C177637 || C198107 || C202136 || C202138 || C33027 || C574	risk_factors || reflux_treatment_type || first_event || exercise_frequency_weekly || extrathyroid_extension || lymph_node_involved_site || immunosuppressive_treatment_type
C	C177537	GDC Value Terminology	C41331	Adverse Event	Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).	Adverse Event | reason_treatment_ended || Adverse Event/Complications | reason_treatment_not_given	C102704 || C166276	reason_treatment_not_given || reason_treatment_ended
C	C177537	GDC Value Terminology	C4139	Combined Carcinoid and Adenocarcinoma	A malignant epithelial neoplasm composed of a mixture of neuroendocrine cells with morphologic and immunohistochemical characteristics of carcinoid tumor and malignant glandular cells.	Combined carcinoid and adenocarcinoma | primary_diagnosis || Combined/mixed carcinoid and adenocarcinoma | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C4146	Chromophobe Renal Cell Carcinoma	A type of carcinoma that comprises a minority of renal cell carcinomas.  It is characterized by loss of chromosomes 1 and Y.  Based on the cytoplasmic characteristics of the neoplastic cells, this type of carcinoma is classified as classic (typical), eosinophilic, or oncocytic.  It has a much better prognosis than other renal cell carcinomas.	8270/3 | morphology || 8317/3 | morphology || Chromophobe adenocarcinoma | primary_diagnosis || Chromophobe carcinoma | primary_diagnosis || Chromophobe cell renal carcinoma | primary_diagnosis || Renal cell carcinoma, chromophobe type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4188	Comedo-Type Adenocarcinoma	A high grade carcinoma characterized by the presence of comedo-type tumor cell necrosis in which the necrotic areas are surrounded by a solid proliferation of malignant pleomorphic cells.	8501/3 | morphology || Comedocarcinoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4314	Odontogenic Fibroma	A rare, benign neoplasm arising from tooth-forming tissues in the mandible and maxilla (central odontogenic fibroma); and rarely from extraosseous tissues, usually in the gingiva (peripheral odontogenic fibroma). It is characterized by the presence of odontogenic epithelium that is embedded in a fibrous stroma. Local enucleation of the tumor is curative.	9321/0 | morphology || Odontogenic fibroma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4315	Peripheral Odontogenic Fibroma	A rare, benign, extraosseous neoplasm arising from tooth-forming tissues. It usually presents as a slow growing exophytic mass in the gingiva. It is characterized by the presence of odontogenic epithelium that is embedded in a fibrous stroma.	9322/0 | morphology || Peripheral odontogenic fibroma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43234	Not Reported	Not provided or available.	Not Reported | adapter_content || Not Reported | adrenal_hormone || Not Reported | ajcc_clinical_m || Not Reported | ajcc_clinical_n || Not Reported | ajcc_clinical_stage || Not Reported | ajcc_clinical_t || Not Reported | ajcc_pathologic_m || Not Reported | ajcc_pathologic_n || Not Reported | ajcc_pathologic_stage || Not Reported | ajcc_pathologic_t || Not Reported | ajcc_staging_system_edition || Not Reported | alcohol_history || Not Reported | alcohol_intensity || Not Reported | alcohol_type || Not Reported | anaplasia_present || Not Reported | anaplasia_present_type || Not Reported | ann_arbor_b_symptoms || Not Reported | ann_arbor_clinical_stage || Not Reported | ann_arbor_extranodal_involvement || Not Reported | ann_arbor_pathologic_stage || Not Reported | antigen || Not Reported | barretts_esophagus_goblet_cells_present || Not Reported | basic_statistics || Not Reported | biospecimen_anatomic_site || Not Reported | biospecimen_laterality || Not Reported | biospecimen_type || Not Reported | bone_marrow_malignant_cells || Not Reported | burkitt_lymphoma_clinical_variant || Not Reported | cancer_detection_method || Not Reported | cause_of_death || Not Reported | cause_of_death_source || Not Reported | cdc_hiv_risk_factors || Not Reported | chemical_exposure_type || Not Reported | chemo_concurrent_to_radiation || Not Reported | child_pugh_classification || Not Reported | chromosomal_translocation || Not Reported | chromosome || Not Reported | chromosome_arm || Not Reported | clark_level || Not Reported | clinical_trial_indicator || Not Reported | cog_liver_stage || Not Reported | cog_neuroblastoma_risk_group || Not Reported | cog_renal_stage || Not Reported | cog_rhabdomyosarcoma_risk_group || Not Reported | columnar_mucosa_present || Not Reported | comorbidities || Not Reported | comorbidity_method_of_diagnosis || Not Reported | consistent_pathology_review || Not Reported | contiguous_organ_invaded || Not Reported | diabetes_treatment_type || Not Reported | diagnosis_pathologically_confirmed || Not Reported | disease_response || Not Reported | disease_type || Not Reported | distance_normal_to_tumor || Not Reported | double_expressor_lymphoma || Not Reported | double_hit_lymphoma || Not Reported | dysplasia_degree || Not Reported | dysplasia_type || Not Reported | ecog_performance_status || Not Reported | education_level || Not Reported | eln_risk_classification || Not Reported | enneking_msts_grade || Not Reported | enneking_msts_metastasis || Not Reported | enneking_msts_stage || Not Reported | enneking_msts_tumor_site || Not Reported | esophageal_columnar_dysplasia_degree || Not Reported | esophageal_columnar_metaplasia_present || Not Reported | exposure_duration || Not Reported | extracapsular_extension || Not Reported | eye_color || Not Reported | figo_stage || Not Reported | first_event || Not Reported | first_symptom_prior_to_diagnosis || Not Reported | gastric_esophageal_junction_involvement || Not Reported | gene_symbol || Not Reported | gleason_grade_group || Not Reported | goblet_cells_columnar_mucosa_present || Not Reported | haart_treatment_indicator || Not Reported | hepatitis_sustained_virological_response || Not Reported | histologic_progression_type || Not Reported | histone_family || Not Reported | histone_variant || Not Reported | history_of_tumor || Not Reported | hormonal_contraceptive_type || Not Reported | hormonal_contraceptive_use || Not Reported | hormone_replacement_therapy_type || Not Reported | hysterectomy_margins_involved || Not Reported | hysterectomy_type || Not Reported | igcccg_stage || Not Reported | imaging_findings || Not Reported | imaging_result || Not Reported | immunosuppressive_treatment_type || Not Reported | initial_disease_status || Not Reported | inpc_grade || Not Reported | inpc_histologic_group || Not Reported | inrg_stage || Not Reported | inss_stage || Not Reported | instrument_model || Not Reported | irs_group || Not Reported | irs_stage || Not Reported | ishak_fibrosis_score || Not Reported | iss_stage || Not Reported | karnofsky_performance_status || Not Reported | kmer_content || Not Reported | laboratory_test || Not Reported | largest_extrapelvic_peritoneal_focus || Not Reported | laterality || Not Reported | lymph_node_involved_site || Not Reported | lymph_node_involvement || Not Reported | lymph_nodes_removed || Not Reported | lymphatic_invasion_present || Not Reported | margin_status || Not Reported | medulloblastoma_molecular_classification || Not Reported | melanoma_known_primary || Not Reported | menopause_status || Not Reported | metaplasia_present || Not Reported | metastasis_at_diagnosis || Not Reported | method_of_diagnosis || Not Reported | method_of_sample_procurement || Not Reported | micrometastasis_present || Not Reported | micropapillary_features || Not Reported | mismatch_repair_mutation || Not Reported | mitosis_karyorrhexis_index || Not Reported | molecular_analysis_method || Not Reported | morphology || Not Reported | necrosis_present || Not Reported | non_nodal_regional_disease || Not Reported | non_nodal_tumor_deposits || Not Reported | normal_tumor_genotype_snp_match || Not Reported | ovarian_specimen_status || Not Reported | ovarian_surface_involvement || Not Reported | overrepresented_sequences || Not Reported | oxygen_use_indicator || Not Reported | parent_with_radiation_exposure || Not Reported | per_base_n_content || Not Reported | per_base_sequence_content || Not Reported | per_base_sequence_quality || Not Reported | per_sequence_gc_content || Not Reported | per_sequence_quality_score || Not Reported | per_tile_sequence_quality || Not Reported | perineural_invasion_present || Not Reported | peripancreatic_lymph_nodes_positive || Not Reported | peritoneal_fluid_cytological_status || Not Reported | peritoneal_washing_results || Not Reported | ploidy || Not Reported | pregnancy_outcome || Not Reported | pregnant_at_diagnosis || Not Reported | premature_at_birth || Not Reported | preservation_method || Not Reported | primary_diagnosis || Not Reported | primary_site || Not Reported | prior_treatment || Not Reported | procedures_performed || Not Reported | progression_or_recurrence || Not Reported | progression_or_recurrence_anatomic_site || Not Reported | progression_or_recurrence_type || Not Reported | radiosensitizing_agent || Not Reported | reason_treatment_not_given || Not Reported | reflux_treatment_type || Not Reported | relationship_primary_diagnosis || Not Reported | relationship_type || Not Reported | relative_deceased || Not Reported | relative_smoker || Not Reported | residual_disease || Not Reported | rhabdoid_present || Not Reported | risk_factor_method_of_diagnosis || Not Reported | risk_factor_treatment || Not Reported | risk_factors || Not Reported | route_of_administration || Not Reported | sarcomatoid_present || Not Reported | satellite_nodule_present || Not Reported | second_gene_symbol || Not Reported | secondhand_smoke_as_child || Not Reported | sequence_duplication_levels || Not Reported | sequence_length_distribution || Not Reported | site_of_resection_or_biopsy || Not Reported | sites_of_involvement || Not Reported | specimen_type || Not Reported | supratentorial_localization || Not Reported | synchronous_malignancy || Not Reported | test_analyte_type || Not Reported | test_result || Not Reported | test_units || Not Reported | therapeutic_agents || Not Reported | therapeutic_levels_achieved || Not Reported | timepoint_category || Not Reported | tissue_or_organ_of_origin || Not Reported | tissue_type || Not Reported | tobacco_smoking_status || Not Reported | transglottic_extension || Not Reported | treatment_anatomic_sites || Not Reported | treatment_effect || Not Reported | treatment_effect_indicator || Not Reported | treatment_frequency || Not Reported | treatment_intent_type || Not Reported | treatment_outcome || Not Reported | treatment_type || Not Reported | tumor_confined_to_organ_of_origin || Not Reported | tumor_depth_descriptor || Not Reported | tumor_descriptor || Not Reported | tumor_focality || Not Reported | tumor_grade || Not Reported | tumor_grade_category || Not Reported | tumor_regression_grade || Not Reported | uicc_clinical_m || Not Reported | uicc_clinical_n || Not Reported | uicc_clinical_stage || Not Reported | uicc_clinical_t || Not Reported | uicc_pathologic_m || Not Reported | uicc_pathologic_n || Not Reported | uicc_pathologic_stage || Not Reported | uicc_pathologic_t || Not Reported | uicc_staging_system_edition || Not Reported | ulceration_indicator || Not Reported | undescended_testis_corrected || Not Reported | undescended_testis_corrected_laterality || Not Reported | undescended_testis_corrected_method || Not Reported | undescended_testis_history || Not Reported | undescended_testis_history_laterality || Not Reported | variant_type || Not Reported | vascular_invasion_present || Not Reported | vascular_invasion_type || Not Reported | viral_hepatitis_serologies || Not Reported | vital_status || Not Reported | weiss_assessment_findings || Not Reported | who_cns_grade || Not Reported | who_nte_grade || Not Reported | wilms_tumor_histologic_subtype || Not Reported | zygosity || not reported | classification_of_tumor || not reported | ethnicity || not reported | gender || not reported | last_known_disease_status || not reported | prior_malignancy || not reported | progression_or_recurrence || not reported | race || not reported | relationship_gender || not reported | relative_with_cancer_history || not reported | treatment_or_therapy || not reported | vital_status	C102562 || C102704 || C104015 || C105721 || C106304 || C106317 || C106541 || C111073 || C112400 || C121007 || C123560 || C125738 || C125904 || C126378 || C127768 || C127772 || C129439 || C13202 || C133427 || C13355 || C133706 || C138899 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C15256 || C154881 || C15599 || C156421 || C156422 || C157233 || C157410 || C157425 || C157437 || C158874 || C159643 || C160720 || C160827 || C160996 || C16124 || C161320 || C16165 || C162221 || C16457 || C16564 || C166229 || C16687 || C17001 || C17049 || C17103 || C171253 || C171435 || C173263 || C173544 || C17357 || C173595 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177570 || C177571 || C177572 || C177576 || C177578 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177616 || C177617 || C177619 || C177620 || C177621 || C177622 || C177624 || C177626 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C17953 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188387 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C198091 || C198092 || C198101 || C198107 || C198139 || C198195 || C198198 || C198201 || C198204 || C198206 || C199145 || C200442 || C200446 || C200469 || C200473 || C202139 || C202140 || C202157 || C202159 || C25185 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C29878 || C2991 || C33027 || C3420 || C35529 || C36037 || C36292 || C38032 || C38114 || C39694 || C4086 || C45824 || C45902 || C4809 || C49236 || C50995 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81180 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C94811 || C95149 || C99532	inpc_grade || reason_treatment_not_given || weiss_assessment_findings || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || double_hit_lymphoma || alcohol_intensity || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || chromosome_arm || mismatch_repair_mutation || double_expressor_lymphoma || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || hysterectomy_type || ulceration_indicator || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || lymph_nodes_removed || lymphatic_invasion_present || satellite_nodule_present || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || comorbidities || ethnicity || tumor_descriptor || histone_family || ploidy || race || risk_factors || second_gene_symbol || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || dysplasia_degree || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serologies || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || initial_disease_status || last_known_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || secondhand_smoke_as_child || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || education_level || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || clinical_trial_indicator || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || cancer_detection_method || chemical_exposure_type || extracapsular_extension || first_event || peritoneal_washing_results || risk_factor_method_of_diagnosis || therapeutic_levels_achieved || timepoint_category || tumor_grade_category || uicc_staging_system_edition || imaging_findings || contiguous_organ_invaded || melanoma_known_primary || relative_smoker || tumor_depth_descriptor || histologic_progression_type || micrometastasis_present || oxygen_use_indicator || radiosensitizing_agent || laterality || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || relative_with_cancer_history || disease_type || lymph_node_involved_site || chromosomal_translocation || lymph_node_involvement || tumor_confined_to_organ_of_origin || test_result || treatment_effect || route_of_administration || sarcomatoid_present || dysplasia_type || zygosity || alcohol_type || residual_disease || treatment_or_therapy || disease_response || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || specimen_type || treatment_anatomic_sites || relative_deceased || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || clark_level || ishak_fibrosis_score || diabetes_treatment_type
C	C177537	GDC Value Terminology	C48728	T3 TNM Finding	A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.	Minimal (T3) | extrathyroid_extension || T3 | ajcc_clinical_t || T3 | ajcc_pathologic_t || T3 | uicc_clinical_t || T3 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448 || C202138	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t || extrathyroid_extension
C	C177537	GDC Value Terminology	C48734	T4b TNM Finding	A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4b TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the pelvic wall and abdominal wall; for gastric cancer it refers to a primary tumor that invades adjacent structures; for colorectal cancer it refers to a primary tumor with direct invasion or adherence to other organs or structures.	T4b | ajcc_clinical_t || T4b | ajcc_pathologic_t || T4b | uicc_clinical_t || T4b | uicc_pathologic_t || Very Advanced (T4b) | extrathyroid_extension	C177635 || C177636 || C188411 || C188448 || C202138	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t || extrathyroid_extension
C	C177537	GDC Value Terminology	C48738	pTis TNM Finding	A term that refers to a TNM finding of a primary tumor microscopically defined as carcinoma in situ.	Stage Tis | ajcc_clinical_stage || Stage Tis | ajcc_pathologic_stage || Stage Tis | uicc_clinical_stage || Stage Tis | uicc_pathologic_stage || Tis | ajcc_clinical_t || Tis | ajcc_pathologic_t || Tis | uicc_clinical_t || Tis | uicc_pathologic_t	C177555 || C177556 || C177635 || C177636 || C188409 || C188411 || C188446 || C188448	ajcc_clinical_stage || ajcc_pathologic_stage || ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_stage || uicc_pathologic_t
C	C177537	GDC Value Terminology	C49487	No	The non-affirmative response to a question.	No | adrenal_hormone || No | alcohol_history || No | anaplasia_present || No | ann_arbor_b_symptoms || No | ann_arbor_extranodal_involvement || No | barretts_esophagus_goblet_cells_present || No | bone_marrow_malignant_cells || No | chemo_concurrent_to_radiation || No | clinical_trial_indicator || No | columnar_mucosa_present || No | consistent_pathology_review || No | diagnosis_pathologically_confirmed || No | double_expressor_lymphoma || No | double_hit_lymphoma || No | environmental_tobacco_smoke_exposure || No | esophageal_columnar_metaplasia_present || No | extracapsular_extension_present || No | gastric_esophageal_junction_involvement || No | goblet_cells_columnar_mucosa_present || No | haart_treatment_indicator || No | hepatitis_sustained_virological_response || No | history_of_tumor || No | lost_to_followup || No | lymph_nodes_removed || No | lymphatic_invasion_present || No | melanoma_known_primary || No | metaplasia_present || No | micrometastasis_present || No | mismatch_repair_mutation || No | necrosis_present || No | non_nodal_tumor_deposits || No | normal_tumor_genotype_snp_match || No | oxygen_use_indicator || No | parent_with_radiation_exposure || No | perineural_invasion_present || No | pregnant_at_diagnosis || No | premature_at_birth || No | prior_treatment || No | progression_or_recurrence || No | radiosensitizing_agent || No | relative_deceased || No | relative_smoker || No | rhabdoid_present || No | risk_factor_treatment || No | sarcomatoid_present || No | secondhand_smoke_as_child || No | synchronous_malignancy || No | therapeutic_levels_achieved || No | treatment_effect_indicator || No | tumor_confined_to_organ_of_origin || No | ulceration_indicator || No | undescended_testis_corrected || No | undescended_testis_history || No | vascular_invasion_present || no | prior_malignancy || no | progression_or_recurrence || no | relative_with_cancer_history || no | treatment_or_therapy	C112400 || C125904 || C127768 || C127772 || C133706 || C138899 || C141342 || C154881 || C159643 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C182060 || C182097 || C182099 || C182109 || C188387 || C18849 || C198198 || C200446 || C200469 || C202137 || C202140 || C202157 || C202159 || C29878 || C36037 || C39694 || C49236 || C81180 || C81229	premature_at_birth || double_hit_lymphoma || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || double_expressor_lymphoma || chemo_concurrent_to_radiation || ulceration_indicator || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || adrenal_hormone || clinical_trial_indicator || history_of_tumor || prior_malignancy || therapeutic_levels_achieved || melanoma_known_primary || relative_smoker || extracapsular_extension_present || micrometastasis_present || oxygen_use_indicator || radiosensitizing_agent || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || relative_deceased || alcohol_history
C	C177537	GDC Value Terminology	C49488	Yes	The affirmative response to a question.	Yes | adrenal_hormone || Yes | alcohol_history || Yes | anaplasia_present || Yes | ann_arbor_b_symptoms || Yes | ann_arbor_extranodal_involvement || Yes | barretts_esophagus_goblet_cells_present || Yes | bone_marrow_malignant_cells || Yes | chemo_concurrent_to_radiation || Yes | clinical_trial_indicator || Yes | columnar_mucosa_present || Yes | consistent_pathology_review || Yes | diagnosis_pathologically_confirmed || Yes | double_expressor_lymphoma || Yes | double_hit_lymphoma || Yes | environmental_tobacco_smoke_exposure || Yes | esophageal_columnar_metaplasia_present || Yes | extracapsular_extension_present || Yes | gastric_esophageal_junction_involvement || Yes | goblet_cells_columnar_mucosa_present || Yes | haart_treatment_indicator || Yes | hepatitis_sustained_virological_response || Yes | history_of_tumor || Yes | lost_to_followup || Yes | lymph_nodes_removed || Yes | lymphatic_invasion_present || Yes | melanoma_known_primary || Yes | metaplasia_present || Yes | micrometastasis_present || Yes | mismatch_repair_mutation || Yes | necrosis_present || Yes | non_nodal_tumor_deposits || Yes | normal_tumor_genotype_snp_match || Yes | oxygen_use_indicator || Yes | parent_with_radiation_exposure || Yes | perineural_invasion_present || Yes | pregnant_at_diagnosis || Yes | premature_at_birth || Yes | prior_treatment || Yes | progression_or_recurrence || Yes | radiosensitizing_agent || Yes | relative_deceased || Yes | relative_smoker || Yes | rhabdoid_present || Yes | risk_factor_treatment || Yes | sarcomatoid_present || Yes | secondhand_smoke_as_child || Yes | synchronous_malignancy || Yes | therapeutic_levels_achieved || Yes | treatment_effect_indicator || Yes | tumor_confined_to_organ_of_origin || Yes | ulceration_indicator || Yes | undescended_testis_corrected || Yes | undescended_testis_history || Yes | vascular_invasion_present || yes | prior_malignancy || yes | progression_or_recurrence || yes | relative_with_cancer_history || yes | treatment_or_therapy	C112400 || C125904 || C127768 || C127772 || C133706 || C138899 || C141342 || C154881 || C159643 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C182060 || C182097 || C182099 || C182109 || C188387 || C18849 || C198198 || C200446 || C200469 || C202137 || C202140 || C202157 || C202159 || C29878 || C36037 || C39694 || C49236 || C81180 || C81229	premature_at_birth || double_hit_lymphoma || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || double_expressor_lymphoma || chemo_concurrent_to_radiation || ulceration_indicator || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || adrenal_hormone || clinical_trial_indicator || history_of_tumor || prior_malignancy || therapeutic_levels_achieved || melanoma_known_primary || relative_smoker || extracapsular_extension_present || micrometastasis_present || oxygen_use_indicator || radiosensitizing_agent || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || relative_deceased || alcohol_history
C	C177537	GDC Value Terminology	C61612	Metformin	An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.	Metformin | nononcologic_therapeutic_agents || Metformin | therapeutic_agents	C1909 || C202155	therapeutic_agents || nononcologic_therapeutic_agents
C	C177537	GDC Value Terminology	C64260	Asparaginase Erwinia chrysanthemi	A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.	Asparaginase Erwinia chrysanthemi | therapeutic_agents || Recombinant Erwinia asparaginase JZP-458 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C72787	Fosaprepitant	A water-soluble, N-phosphorylated prodrug of the substance P (SP; neurokinin 1 (NK1)) antagonist aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent selectively binds to and blocks the human substance P receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.	Fosaprepitant | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C76115	Aderbasib	An orally bioavailable inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity. Aderbasib represses the metalloproteinase 'sheddase' activities of ADAM10 and ADAM17, which may result in the inhibition of tumor cell proliferation. The metalloproteinase domains of ADAMs cleave cell surface proteins at extracellular sites proximal to the cell membrane, releasing or "shedding" soluble protein etcodomains from the cell surface; the disintegrin domains of these multifunctional proteins interact with various components of the extracellular matrix (ECM). ADAM10 processes particular epithelial growth factor receptor (EGFR) ligands and appears to regulate Notch signaling through the cleavage of Notch and its related ligand delta-like ligand-1 (Dll-1). ADAM17 (also known as Tumor necrosis factor-Converting Enzyme or TACE) is involved in processing tumor necrosis factor (TNF) from its membrane bound precursor to its soluble circulating form and in processing ligands for the epidermal growth factor receptor (EGFR) family.	Aderbasib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C78476	mTOR Kinase Inhibitor CERC-006	An orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor, with potential antineoplastic activity. Upon oral administration, mTOR kinase inhibitor CERC-006 binds to and inhibits both the raptor-mTOR (TOR complex 1 or TORC1) and the rictor-mTOR (TOR complex 2 or TORC2) complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR is a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.	mTOR Kinase Inhibitor OSI-027 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C80338	Hypodiploid B Lymphoblastic Leukemia/Lymphoma	A precursor lymphoid neoplasm composed of B-lymphoblasts which contain less than 46 chromosomes. It has an unfavorable clinical outcome.	9816/3 | morphology || B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL) | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C80867	Cediranib	An orally bioavailable indole ether quinazoline derivative and vascular endothelial growth factor receptor (VEGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, cediranib binds to and inhibits the three VEGFR subtypes 1 (VEGFR-1), 2 (VEGFR-2) and 3 (VEGFR-3), thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Expression of VEGFRs may be upregulated in a variety of tumor cell types.	Cediranib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C82423	Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214	An acute myeloid leukemia associated with t(6;9)(p22.3;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.	9865/3 | morphology || Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214 | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C82426	Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM	An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.	9869/3 | morphology || Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C88272	Fexagratinib	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.	FGFR Inhibitor AZD4547 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C88311	Momelotinib	An orally bioavailable small molecule inhibitor of wild-type (WT) Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant form JAK2V617F, and activin A receptor type 1 (ACVR1; activin receptor like kinase 2; ALK2), with antineoplastic activity. Upon oral administration, momelotinib competes with JAK1/2 for ATP binding, which results in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and leads to the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. In addition, the inhibition of ALK2 prevents liver hepcidin formation, increases iron availability and increases red blood cell (RBC) production. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.	Momelotinib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C9288	Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1	An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.	9896/3 | morphology || Acute myeloid leukaemia, t(8;21)(q22;q22) | primary_diagnosis || Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 | primary_diagnosis || Acute myeloid leukemia, AML1(CBF-alpha)/ETO | primary_diagnosis || FAB M2, AML1(CBF-alpha)/ETO | primary_diagnosis || FAB M2, t(8;21)(q22;q22) | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C93286	Radiologic Examination	The use of x-rays, or other radiologic imaging modalities, for visualizing body spaces and organs, usually for diagnosis or screening of disease.	Radiologic | measurement_type	C200444	measurement_type
C	C177537	GDC Value Terminology	C95769	Crystalline Genistein Formulation AXP107-11	The sodium salt dihydrate form of crystalline genistein, a soy-derived isoflavone and phytoestrogen, with potential antineoplastic, chemosensitizing, and antioxidant activities. Upon administration, crystalline genistein formulation AXP107-11 binds to and modulates the activities of the nuclear estrogen receptors ERalpha (ESR1) and ERbeta (ESR2), and activates the G-coupled estrogen receptor 1 (GPER1). In addition, this agent increases the expression of phosphatase and tensin homolog (PTEN), which deactivates protein kinase Akt and mitogen-activated protein kinases (MAPK1 and 3; ERK2 and 1), thereby disrupting PI3K/Akt signal transduction and inducing apoptosis. AXP107-11 also induces antioxidant enzymes through AMP-activated protein kinase (AMPK) activation, inhibits nuclear factor kappa-B (NF-kB) activation and decreases inflammation response, thereby sensitizing tumors to chemotherapy. Compared to genistein itself, which has poor oral availability, this crystalline formulation shows improved solubility and bioavailability.	Crystalline Genistein Formulation AXP107-11 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C95921	pN0 (i-) TNM Finding	A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically, and immunohistochemistry is negative.	N0 (i-) | ajcc_clinical_n || N0 (i-) | ajcc_pathologic_n || N0 (i-) | uicc_clinical_n || N0 (i-) | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95922	pN0 (i+) TNM Finding	A regional lymph node TNM finding indicating that there are malignant cells in regional lymph node(s) no greater than 0.2 mm and are detected by hematoxylin and eosin stain or immunohistochemistry.	N0 (i+) | ajcc_clinical_n || N0 (i+) | ajcc_pathologic_n || N0 (i+) | uicc_clinical_n || N0 (i+) | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95923	pN0 (mol-) TNM Finding	A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and molecular analysis (RT-PCR) is negative.	N0 (mol-) | ajcc_clinical_n || N0 (mol-) | ajcc_pathologic_n || N0 (mol-) | uicc_clinical_n || N0 (mol-) | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95925	pN0 (mol+) TNM Finding	A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and by immunohistochemistry, but the molecular analysis (RT-PCR) is positive.	N0 (mol+) | ajcc_clinical_n || N0 (mol+) | ajcc_pathologic_n || N0 (mol+) | uicc_clinical_n || N0 (mol+) | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C96025	pTa TNM Finding	A term that refers to a TNM finding of a primary, non-invasive, papillary cancer.	Ta | ajcc_clinical_t || Ta | ajcc_pathologic_t || Ta | uicc_clinical_t || Ta | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t